Podcasts about Shulman

Derek Shulman and John Weathers never looked back, and maybe that's why Gentle Giant's music still stares you The post Gentle Giant's Derek Shulman and John Weathers appeared first on The Strange Brew .

Dr. John Sweetenham, Dr. Larry Shulman, and Dr. Rebecca Maniago discuss the integration of clinical pathways and decision support tools into the cancer center workflow, challenges to implementation at the point of care, and the promise of AI to further unlock these tools for clinicians. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast. Over the last decade or so, there has been a great deal of work and a lot of discussion about the implementation of oncology clinical care pathways at the point of care, which are designed to reduce variability in care, reduce costs, and improve the quality of care and outcomes. Although clinical pathways aim to guide treatment decisions, current data suggests that the utilization of these pathways at the point of care is very low. There are many reasons for this, which we will get into on the episode today.   My guests today are Dr. Larry Shulman and Rebecca Maniago. Dr. Shulman is a professor of medicine at the University of Pennsylvania Abramson Cancer Center. He's also the immediate past chair of the Commission on Cancer and serves on the National Cancer Policy Forum of the National Academies of Sciences, Engineering and Medicine. Rebecca Maniago is the director of clinical oncology at Flatiron Health, a technology platform that collects and analyzes real-world clinical data from electronic health records to facilitate decision making and research.  Our full disclosures are available in the transcript of this episode. Larry and Rebecca, welcome to the ASCO Daily News Podcast and many thanks for being here.  Dr. Larry Shulman: Thank you, John.  Rebecca Maniago: Thank you for having me.  Dr. John Sweetenham: Larry, I'm going to start out, if I may, with a question for you. You and I, in a previous podcast, have discussed some of these issues regarding pathway implementation before. But to start out with, it's certainly, I think, helpful for the listeners to remind us all of what are the benefits of oncology clinical pathways and why are we still talking about this 10 years or more on.  Dr. Larry Shulman: Yeah, and that's a great question, John. I think the good news is, and all of us who live in the oncology sphere know this, that there's been tremendous progress in cancer therapies over the last decade. But what that has entailed is the introduction of many new therapies. Their complexity is becoming really very tough for people to manage.  And so what we have are oncologists who are really trying to do their best to deliver care to patients that will give them the best chance for survival and quality of life. But it's really, really hard to keep up with everything that's happening in oncology in the context of what we all know is a very busy clinic schedule. Lots of patients coming through and decisions need to be made quickly. Pathways really could help us to guide us into recommending and delivering the best therapies for our patients for a particular disease. You know, cancer is complicated. There are many different types and there are many different therapies. It's just a lot to deal with without some assistance from pathways or pathway tools.  Dr. John Sweetenham: Thanks, Larry. So, knowing that's the case and knowing that these tools reduce variability, improve costs, improve quality of care as well. Starting with you again, Larry, if I may, why do you think it's been so difficult for so many oncologists to use these pathways effectively at the point of care?  Dr. Larry Shulman: So, I just wanted to step back a little bit. There are very extensive guidelines that tell us what the best therapies are for really all of the cancers. These guidelines come from the National Comprehensive Cancer Network or NCCN and the American Society of Clinical Oncology or ASCO and other professional organizations. And they're there. They're there, in free information off their websites.  But the problem is how to translate those pretty dense documents into something that will work in the clinic for a patient, for the physician who's working in the electronic health record. And the tools that are available, and there are a number of tools that can integrate with electronic health records, are expensive. You need to purchase them from the vendor and there are yearly fees.  And they're also difficult to implement. You need to work with the vendor to integrate them into your own rendition of your electronic health record. And there's a lot of customization that needs to be done. So, it's a financial challenge and it's also a time challenge for people to integrate these tools into their workflow, into their electronic health records.  Dr. John Sweetenham: Thanks, Larry. So speaking from my own past experience of pathway implementation, it certainly has been a major challenge for the reasons that you mentioned and also because of the, I think resistance may or may not be too strong a word, of many of the clinicians to use these for a number of reasons, part of which are the time it takes, part of which many of them feel that the pathways aren't really changing decisions that they might make anyway. So, you know, the uptake of pathway utilization, even in those centers which have been successful in getting something installed and plugged into their EHR, on the whole, hasn't been as good as it could have been. So maybe I'll turn to you, Rebecca, because I know that this is something that you've worked on a lot.  And it's a kind of double-barreled question. I think the first part of it is, you know, what do you think are the major roadblocks to high physician uptake in the use of these pathways platforms? And maybe you could talk a little bit about what the various software platforms do to make them more physician-friendly and to enhance utilization right on the front line.  Dr. Rebecca Maniago: Yeah, that's a great question. And so, you know, I've worked with a number of customers and physicians over the past five and a half years on implementing these pathways. And the number one pushback is really about the time it takes in the workflow. So, if I had a dollar for every time I heard “every click counts,” I'd be a rich person and it does come down to clicks. And so, you know, as a software vendor, we really have to focus on how do we reduce that friction?  How do we make sure that the clicks we are asking for are the ones that actually matter? And how do we continue to streamline that process? And so, you know, while there is a fine balance, because as part of a Pathways platform, at the end of the day, we do need to understand some data about that patient. You need to understand the clinical scenario so you can surface the right treatment recommendation, which means there is some amount of data capture that has to happen. In some circumstances, you know, we can pull some of that data in from the EHR.  But unfortunately, the reality is that a lot of that data is messy and it's sort of stuck in documents and unstructured places. And so it doesn't easily flow in, which means we rely on the provider to give us that information. And oftentimes they've already entered it other places. So what's more frustrating than entering data twice? But, you know, I do see a great opportunity here. And this is certainly where software companies are focused is with AI.  So, know, for, especially for this data aggregation, a lot of these AI tools can actually scan through the chart instead of relying on the physician to sort of manually skim through and aggregate and find all that pertinent information. That's what AI is really good at. And almost instantaneously, it can find the messy data that lives in those unstructured documents. And wouldn't it be nice if that was automatically populated within these applications so that really all we're asking of the clinician is to validate that that information is accurate. And then choose the treatment that cuts down on the number of clicks, it cuts down on frustration. You know, again, the physician will be the one that needs to make that decision. AI is not there to replace that, but it certainly has a great opportunity to reduce some of this manual documentation and the things that physicians find the most frustrating, especially as it relates to using these pathways tools.  Dr. John Sweetenham: One of the pretty common pushbacks that I heard during my time in a couple of institutions was, “Well, you know, I'm sitting here at the point of care with my patients and I already know what I want to do and how I'm going to treat that patient if it's not in the context of a clinical trial. So I don't need to go through, you know, X number of clicks to get me to where I know I'm going to be anyway.”  Does either of you have any thoughts about that? I think you've sort of partially answered it, but what do you think, Rebecca? Do you think that this is something that is more easily overcome-able, if that's even a word, than it was a few years back?  Rebecca Maniago: Yeah, I do. And I think this is where the customization comes into play. So while they may know what an appropriate treatment for their patient is, there are more options now than ever, which means at a local level, there may be multiple options that are clinically equivalent. And so when you think about things like payer pathways or drug margins as an organization, they have to drive some of that from within. But having the capability to do so can then start to sort of sell the value to the provider that, yes, you may know what you want to order for your patient, but would you consider something else if it was clinically equivalent, but it had other benefits to either the patient or the organization?  Dr. Larry Shulman: The other thing I would add to that, John, if I can jump in here is that the data is the data and the data shows us that guideline concordant care is not always prescribed to the US. And in fact, in some circumstances, the gaps between what should be prescribed and what is being prescribed are quite wide. So, you know, people feel like they're always doing the best job and making the best recommendations. And I think, you know, I think I am. But, you know, like many of my colleagues at academic cancer centers, I'm highly specialized. I only see patients with breast cancer. But many oncologists throughout the country are more generalists. They're seeing patients with multiple diseases. And it's harder for them to be completely on top of what the current recommendations are in any particular circumstance. Our diseases are complicated. They're getting more complicated all the time with molecular and genomic testing and subcategorizations of different cancers. So, I don't think that we can be too cocky about it, quite frankly. I think we ought to use technology that Rebecca describes for the tools and for AI to really help us. I think if we turn our backs on that, I think we're making a big mistake. You just got to look at the data. The data is pretty convincing.  Dr. John Sweetenham: You know ever since we started looking seriously at decision support through pathways a number of years ago, the word has always been around the payers role in this and the day will come where we are going to get reimbursed based on pathway and concordance and I'm not sure that that day has arrived. So I have a question for both of you in this regard actually. And the first of those is maybe I'll start with you for this part of it, Larry. Where do you think we are in that regard? And are you hearing more and more of payers starting to look at pathway compliance? And then on the other end of that, and maybe I'll ask Rebecca about this, is one of the other pushback issues that I used to experience from physicians I worked with was they may go through the pathways platform and come up with a treatment recommendation. The best example of this I can think might be that the recommendation might be a biosimilar. Let's just use that as an example. But the next stage in the process would be to find out whether the patient's insurance would actually cover that particular biosimilar, which opened up a whole new can of worms. So there are two kinds of payer aspects of that. Maybe Larry, I'll ask you to start off by talking about that kind of coverage issue. And then I'll ask Rebecca, if you have any thoughts about the flow the other way in terms of getting drugs approved and what we can do to help from an insurance perspective.  Dr. Larry Shulman: Sure, that's really an important point, John. Our current state of affairs with the payers and their attempt to be sure that we're providing responsible, guideline concordant care is the use of prior authorization processes, which are incredibly costly, both for the oncology practices and for the payers.  They have an army of nurses sitting at the phone talking to us in the oncology practices to decide whether they're going to pay for something. And frankly, generally, the payers will pay for things that are part of either the NCCN or ASCO or other professional organizations' guidelines. But you need to prove to them over the phone that in fact the patient qualifies for that.  We have actually had some experiments with some of the payers to prove that to them in different ways by auto transmission of data. And this would be a big savings for them and for us, it would take away some of the delays in therapy while we're waiting for prior authorizations to go through. And we shouldn't have to do this by phone.   The EHR and the pathway tools should aggregate the data, aggregate the potential treatment and be able to transmit those data to the payer. And if in fact it meets the appropriate criteria for guideline concordant care would be approved. Right now, it's a terrible, costly, timely manual process that they should be able to fix.  Dr. John Sweetenham: Thanks, Larry. And have you, you know, from a broader perspective, so not thinking necessarily about individual patients and specific issues around prior authorization, have you seen any movement among the payers to kind of get more aggressive about this and say, okay, you know, we are going to want to see your numbers, we want to know how many of your physicians are now using their pathways platform and so on. Are you seeing any word that that might be happening? Because certainly a few years back, that was the word on the street, as it were, that this day was coming.  Dr. Lawrence Shulman: And that's the proposal that we've made to several of our payers. Let us give you the aggregate data. If our guideline concordance is above a certain level, give us a gold card, give us a pass, and we won't need to do pre-authorizations. We've actually done that at my institution in radiology. Aggregate data gives individual physicians that pass if their guideline concordance was appropriate. I got to pass. So I don't need to go through those radiology pre-authorizations for my patients. And I think we can do the same thing with therapeutics. It's been a little bit more cumbersome to do it, and there's some detailed reasons why that is. But that's really what they want to know. And the payers want to know that patients are getting guideline concordant care, but they also realize it's not going be 100%. There are always a few outlier patients who require some variation from the guidelines. But if we get above 80% guideline concordant care, I think many of the payers would be happy to accept that as long as we continue to feed them the data. And that's the case in our radiology process with one of the payers is, you know, I get a gold card, but they continue to look at my data. And if I don't continue to perform well, they'll take that away.  Dr. John Sweetenham: Thanks, Larry. And Rebecca, just returning to you, this issue of prior authorization and facilitating life for the physician at the point of care in terms of knowing, you know, which specific treatment might be covered for a patient. Do you have any thoughts or maybe you could give us some insights on what software vendors are doing to facilitate that part of the process, the communication back to the payers to take some of that burden off the physician and the physician staff?  Rebecca Maniago: Yeah, absolutely. And this is a problem we've been trying to tackle for years. And it's not easy. We've tackled it in a couple ways. So first, we try to sort of link up to the payer portal where the information that was being attested to within the application could then be automatically sent. Because at the end of the day, the data points that are being collected to surface treatment recommendations ultimately are the same data points that the payer wants.  Unfortunately, there are a lot of data interoperability challenges within that space. So that was not something that was going to be sustainable. However, in current state, because as I mentioned, the customization is key for these products, focusing more on how can we allow practices to embed payer pathways within the application. So again, you kind of start with the backbone of your standard guidelines but then having the capability of adding in a payer pathway that will only show up as that preferred option for a patient who has that insurance, at least at the point of care, the provider sees what the insurer would then approve. So while it's not automatically assuring authorization, we are at least steering the decision in a direction where we think most likely this is going to be approved based upon the pathway that they have access to. So that sort of current state, I agree. We've been talking about this idea of gold carding for years.  Presumably the data is there today, right? Like we are able to capture structured data with every order placed to recognize concordance to Larry's point. All those reports are available to provide to payers. I just haven't seen a lot of practices have a lot of success when they tackle it on their own from that direction.  Dr. John Sweetenham: Right, thanks. Larry, you and I were at the NCCN annual meeting recently and I know that you've been quite heavily involved in the policy program and in the policy forums and so on at NCCN. Are you able to share anything from this year's meeting in terms of care pathways implementation and what you think might happen next in that regard?  Dr. Larry Shulman: NCCN, in my own opinion, has really led the way in defining what guideline concordant care is through their guidelines, which are very extensive, covering basically every cancer and every situation with every cancer. And it's really an astounding amount of amazing work that all of us use and the payers largely use as well. But they've increasingly understood that there's a gap between their guidelines and the implementation of their guidelines. And they are working on some things. They are working on the digitalization of their guidelines to make them more accessible, but also thinking about ways that they may, in fact, fit into the work processes that all of us have when we go to clinic.  They're acutely aware that the country is not where it needs to be in regard to a translation, if you will, of their guidelines in the practice. And I think we're all thinking really hard about whether there are things that we can team up to do, if you will, to try to close those gaps.  Dr. John Sweetenham: Great, thank you. Just switching gears a little bit back to you, if I can, Rebecca. I think you've said a little bit about this already. What do you think are the next steps that we need to take to more effectively implement these tools in the clinic? I think we've discussed a little bit some of the roadblocks to that. But where do you think we need to go next in terms of getting better use of these pathways?  Rebecca Maniago: Yeah, I will say one thing that we haven't really touched on is the pharmacy team. So the biggest blocker that I see is actually the pre-implementation. So there's a lot of focus on how do we get physicians to use this? How do we increase adoption? But often the first barrier is the regimen library. So no matter what the pathways platform is, the backbone of it will be those regimens. And so, really helping organizations and we partner with pharmacies, they're doing all the backend configuration. And so how can we make that piece of the technology easier for them to implement because that's really the lead up and there's a ton of cleanup and maintenance. You know, as a pharmacist, I empathize, but really that's where it all begins. And so I think, you know, continuing to focus on not only the front end user and the physician, but everybody that's going to be involved in order to make a pathway program successful needs to be, you know, at the table in the beginning, helping set up those processes and, and buying into the why this is important.  Dr. John Sweetenham: That's a great point.  Dr. Larry Shulman: So could I just jump in one quickly here, John? So pathways, as we've discussed, the tools are expensive. There is a person cost, as Rebecca is just describing, about customization and implementation. But there are very good data in the literature to show that when you follow pathways, care is less costly. Survival is better, which is obviously our primary goal, but also cost is less. And the payers can benefit from that. And the question is, can they figure out ways to use that to help to fund the purchase and maintenance of pathway products that will give their patients better care, but also less costly care? And so I think that is a potential solution. I've had that conversation with some payers as well. And it would be great to see that happen. I think that would be a huge step.  Rebecca Maniago: Yeah, we have some, if they're able to set it up in the right way and really optimize, you know, from the pharmacy perspective, we have practices who the application is more than, you know, paying for itself just by way of using it to the fullest potential that it has.  Dr. John Sweetenham: Yeah, that's a really great point. A couple of other more general questions. I'm going to start with you, Rebecca, and Larry ask you to respond as well. Are you hearing anything from patients around this issue? Are they aware or becoming more aware that pathways are being used in the clinic when they're seen by their physicians? And do they have a say, are there patient advocates involved in this part of the process? Rebecca, maybe you could start.  Rebecca Maniago: I haven't had as much exposure to that side of it. So, you know, I would love to hear what Larry thinks because most of my exposure is at the physician level, which of course they are the ones who are making the decision with the patient. So my assumption is that there is at least some level of understanding that there are options and that, you know, together let's decide on the best one for you. But again, I would love to hear what Larry has to say.  Dr. Larry Shulman: Yeah, so that's a really interesting question. I actually was discussing that at the cancer center last week, particularly around the utilization of AI in this process. And, you know, right now, as you know, if you submit a journal article or, you know, many other things, ask you whether you used AI to generate it. If in fact we use tools that include AI, we're not.  Are we obligated to tell the patient that you're making this recommendation together with computer assist, if you will, that helps you to make the recommendation you are making to them? Ultimately, I think it's the physician who's responsible for the choice, but should we disclose it? I have to tell you personally, I haven't thought about doing that. But I think it's a really, really good question is whether we should upfront tell the patients that we've had assistance in making the recommendations that we have.  Dr. John Sweetenham: Right, very interesting point. To close it out, one more question for both of you and again, it's the same one. Rebecca, to start with, we've all been, as I said right up front, talking and, you know, working on this issue for more than 10 years now. In 10 years from now, how would you like it to look and how do you think it might look?  Rebecca Maniago: Great question. I think we may get to where I would like to see it quicker than 10 years. I think AI provides a lot of opportunity and excitement. I'd love to turn a corner where physicians no longer see tools like this as a hindrance, rather they rely on them, they trust them, they help them get through their day. They continue to improve quality of care and reduce costs and patient burden. Obviously, that's the pipe dream, but I think we may get there before 10 years, given what I think AI is going to enable.  Dr. Larry Shulman: Yeah, I want to add to Rebecca's comments. One of the things that I worry about, and ASCO worries about a lot, is the oncology workforce, which is progressively strained in their attempts to care for all the cancer patients in the US. And for all of us who practice oncology, for many reasons, it's become more and more inefficient, whether it's use of the EHR, pre-authorization work, and so on.  And we really need to turn that around. We need to make practice not only better, which I think these tools can do, including AI, as Rebecca says, but make it much more efficient because that's going to allow us to both deliver more high-quality care to our patients, but also to care for more patients and have them benefit from our expertise and what we have to offer. So I think this is really an obligation on our part. I think it's an imperative that we move in this direction for both quality reasons and efficiency reasons.  Dr. John Sweetenham: Thanks, Larry. Well, I've really enjoyed the conversation today and I think, you know, it's been great to think about some of the challenges that we still have in this regard. But it's also great to hear what I'm sensing is quite a lot of optimism about how things may play out over the next few years. And it does sound as if there's a lot of hard work going on to bring us to a point where the clinical decision support tools are going to truly support what our oncologists are doing and no longer be seen as an obstruction. So, I want to thank you both for sharing your insights with us today on the ASCO Daily News Podcast.  Dr. Larry Shulman: Thank you so much, John.  Rebecca Maniago: Thank you so much.  Dr. John Sweetenham: And thank you to our listeners for your time today. If you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts.  Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:  Dr. John Sweetenham  Dr. Lawrence Shulman  Rebecca Maniago  Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn        Disclosures:  Dr. John Sweetenham:  No relationships to disclose    Dr. Lawrence Shulman:  Consulting or Advisory Role: Genetech     Rebecca Maniago:   No relationships to disclose.     

Divorce is complicated. Having to go through the process of getting a lawyer and splitting assets can be a challenge. But what if you and your partner own a business together? That's where things can get complicated. Laura Paris, associate lawyer at Shulman & Partners LLP, joins us to take us through on what happens to your business when you are going through a divorce. Find out more at shulman.ca and connect on Instagram, X/Twitter and Facebook.

A personal finance book for teenagers. Shannon Lee Simmons, certified financial planner, chartered investment manager, life coach and author, takes us through Making Bank: Money Skills for Real Life.  Then, the financial cost of ignoring burnout. Olga Morawcynski, founder of Heal-3 and a mental wellbeing advocate, tells us about her journey.  And, how joint business ownership can complicate a divorce. Laura Paris, family lawyer with Shulman & Partners, takes us through the process.  Plus, we speak with Juan Sebastian D'Achiardi, of TransUnion Canada, about its TruVision Trended Risk Score. To find out more about the guests check out: Shannon Lee Simmons: Shanno Lee Simmons(IG) | New School of Finance(IG) Juan Sebastian D'Achiardi: LinkedIn | Instagram Heal-3: heal-3.com | LinkedIn Olga Morawcynski: LinkedIn Laura Paris: shulman.ca | Instagram | X/Twitter | Facebook Bruce Sellery is a personal finance expert and best-selling author. As the founder of Moolala and the CEO of Credit Canada, Bruce is on a mission to help you get a better handle on your money so you can live the life you want. High energy & low B.S., this is Moolala: Money Made Simple. Find Bruce Sellery at Moolala.ca | Twitter | Facebook | LinkedIn

Send us a textWelcome to another insightful episode of Business Growth Talks with Mark Hayward. This week, our guest is sales guru Eric Shulman, the brains behind Truth Based Selling—a methodology designed to enhance sales conversations with honesty and client-focused clarity. During the episode, Eric shares his rich journey from a music store family business to becoming a towering figure in the world of sales training. His foundational belief is that authentic communication and truthful interactions are pivotal in making sales processes more effective and building lasting client relationships.In this episode, Eric Shulman digs into the realities of scaling a business and the pivotal role of sales in this journey. Through SEO-focused insights, Eric explains how entrepreneurs can harness the power of effective communication and authentic client interaction in sales strategies. The conversation touches on essential concepts like diagnosing before prescribing, nurturing client relationships, and the importance of knowing when to pivot in business ventures. Eric's innovative ideas challenge traditional sales norms and advocate for strategies that make sales a client-centric, ethical process. Listen to Eric as he shares compelling anecdotes and actionable advice that promise to enrich your business acumen.Key Takeaways:Truth Based Selling emphasizes genuine communication and problem-solving over aggressive sales tactics, making interactions more client-focused and less adversarial.Diagnosing before prescribing is critical; understanding a potential client's needs and challenges should always precede offering solutions.Embrace entrepreneurial spirit by betting on oneself and pivoting when necessary, which can turn ideas into successful business ventures.Communication psychology plays a significant role in sales. Understanding behavioral cues and emotional triggers can enhance how sales professionals engage with potential clients.Legacy in sales involves positively impacting clients' lives by ethically helping them solve their problems, thereby creating long-lasting professional relationships.Resources:Eric Shulman's Website: Consultants Can SellSandler Training: Sandler TrainingBook Reference: "Games People Play" by Dr. Eric BerneListeners are encouraged to tune into this content-rich episode to glean actionable insights tailored for anyone passionate about elevating their sales strategy or business. Stay connected for more episodes featuring transformative discussions with seasoned industry experts.Support the showIf you want to watch the full video of this episode go to:https://www.youtube.com/@markhayward-BizGrowthTalksDo you want to be a guest on multiple podcasts as a service go to:www.podcastintroduction.comFind more details about the podcast and my coaching business on:www.businessgrowthtalks.comFind me onLinkedIn - https://www.linkedin.com/in/mark-hayw...Tik Tok - https://www.tiktok.com/@mjh169183YouTube Shorts - https://www.youtube.com/@markhayward-BizGrowthTalks/shorts

Mikey Shulman is having a great time. He's running a rocket ship of a company, has $100M+ in funding from some of the top VCs, and is working on an opportunity that he's passionate about. Mikey hit my radar because of a text from my friend TJ. His firm was an early backer of Suno, and he said that if any company they work with was going to hit our “4 Min Mile” challenge of $100M in revenue with fewer than 10 employees, it'd be Suno. That was the conversation I was planning to have with Mikey when we stepped into the studio at Suno HQ in Cambridge. What unfolded was a conversation with much more nuance and range than I'd originally anticipated. Some takeaways:Mikey emphasizes the importance of fun in AI development, contrasting with the industry's focus on productivity gains. He sees AI as a tool for enhancing human creativity in music, potentially leading to new heights in artistic expression.Shulman sees AI as a tool that, like humans, learns from past data to create new expressions. He disagrees with the notion that AI can only look backward, arguing that it can be a powerful instrument for innovation in music when guided by human creativity.The company's rapid growth was aided by staying somewhat removed from the AI hype cycle, allowing them to focus on building value and iterating quickly based on user feedback.Despite raising significant capital, Shulman actively tries to avoid fixating on the company's war chest. He believes constantly thinking about available funds can distort decision-making and lead to inefficient resource allocation.Shulman credits much of Suno's success to his talent for hiring and building a strong team, rather than his own ideas. He stresses the value of finding people who are passionate and committed to the company's mission.As Suno approaches the $100M mark with a much bigger team than 10, I can't help but wonder if there's more indie can be doing to encourage and support founders who are thinking similarly about small teams with ambitions for massive scale. We're doing that already through our direct investing, but I wonder if there's a program we could put together that would involve investment and shared learnings from a group of like-minded founders working towards a similar goal that could help the whole get there that much quicker. If you have thoughts on this, please share. It's something we're actively thinking through, and I would value additional ideas and points of view. As always, we hope you enjoy watching this one as much as we enjoyed recording it. If you're working on something with a similar ethos to Suno and looking for investment, don't hesitate to reach out. — Bryce

The Mark Moses Show is joined by Head Basketball Coach Jeremy Shulman of UT-Martin to recap his first year on campus, what he learned from his time coaching at Eastern Florida State College and his thoughts on the NCAA Tournament heading into Sweet 16 Matchups later this week in the world of College Basketball.  Mark is also joined by Tim Walters of The Florida Today to talk about his career, his love for sports on the Space Coast and his picks for Match Madness kicking off this week in the world of College Basketball.  Mark broadcasts from the Anidjar & Lavine Accident Attorneys Studio.    #Podcast #MosesShow #Basketball, MarchMadness #Interview 

As we prepare for a future traveling the stars, energy-efficient processing technologies will be a necessity for both those in space and those remaining as Earth's stewards. Holly Shulman, research professor at Alfred University, shares how she became interested in microwave sintering, describes its benefits compared to conventional sintering processes, and explains how it could support the development of future lunar colonies.View the transcript for this episode here.About the guestHolly Shulman is research professor at Alfred University and founder, president, and chief technology officer of Bluestar Advanced Manufacturing. She specializes in developing microwave processing technologies, and she was recently named director of the new Space Materials Institute at Alfred University in part due to the potential applications of her research on the moon. She will be giving a talk on microwave processing for lunar construction at the 59th Annual Microwave Power Symposium in June 2025, and she plans to teach an ACerS short course in the near future.About ACerSFounded in 1898, The American Ceramic Society is the leading professional membership organization for scientists, engineers, researchers, manufacturers, plant personnel, educators, and students working with ceramics and related materials.

Fund manager Dr. Joel Shulman is bringing private equity access to retail investors. Meet XOVR, the exchange-traded fund that includes private holdings like SpaceX—typically only available to big institutions or cashed-up individuals. Hear how deferred IPOs have made private equity a $13 trillion market, and why Dr. Shulman believes there’s still massive growth potential, even dwarfing cryptocurrency. Discover the risks and advantages of XOVR, the unique entrepreneurial index it tracks, and the implications of including private assets that trade much more slowly. Plus, how do Elon’s recent controversies impact XOVR’s substantial SpaceX holdings? For more or to watch on YouTube—check out http://linktr.ee/sharedlunch Shared Lunch is brought to you by Sharesies Limited (NZ) in New Zealand and Sharesies Australia Limited (ABN 94 648 811 830; AFSL 529893) (collectively referred to as ‘Sharesies’). Appearance on Shared Lunch is not an endorsement by Sharesies of the views of the presenters, guests, or the entities they represent. Their views are their own. Shared Lunch is not personal financial advice and provides general information only. We recommend talking to a licensed financial adviser. You should review relevant product disclosure documents before deciding to invest. Investing involves risk. You might lose the money you start with. Content is current at the time.See omnystudio.com/listener for privacy information.

John Shulman is the Founder and President of Alignor, a negotiation expert with Harvard credentials, and a consultant to business leaders worldwide. This episode is all about the art of negotiation—from handling tough procurement conversations to defending price in a world of price-focused buyers.Learn about the interest-based negotiation approach, where it aligns (or conflicts) with today's high-stakes sales environment, and how AI is reshaping the way we negotiate. If you are looking for sharpen your negotiation skills and close better deals real with world strategies and insights, this episode is a must-listen.Are you interested in leveling up your sales skills and staying relevant in today's AI-driven landscape? Visit www.jbarrows.com and let's Make It Happen together!Connect with John on LinkedIn: https://www.linkedin.com/in/johnbarrows/Connect with John on IG: https://www.instagram.com/johnmbarrows/Check out John's Membership: https://go.jbarrows.com/pages/individual-membership?ref=3edab1 Join John's Newsletter: https://www.jbarrows.com/newsletterConnect with John Shulman on LinkedIn: https://www.linkedin.com/in/john-shulman-1b12202/?Check out John Shulman's Website: https://www.alignor.com/

Shulman v. Collins

In this episode of Daily Influence, host Gregg-Brooke Koleno sits down with Joyce Shulman—coach, author, and business igniter—who helps women navigate the intersection of personal and professional growth. Joyce shares insights from her entrepreneurial journey, from launching businesses in consumer products and media to creating impactful wellness brands.She introduces her 10 Touch Strategy, a powerful framework for fostering meaningful relationships and business success. Together, they explore the importance of integrating work and life, overcoming time constraints, and prioritizing relationships with intention. Joyce also reveals her own journey in setting boundaries and making time for personal joy—proving that business is personal.Join us for a conversation on leadership, connection, and the small, consistent actions that create a lasting impact. Tune in now and start embracing influence with purpose!

Liz Shulman, English teacher at Evanston Township High School and in the School of Education and Social Policy at Northwestern University, joins John Williams once again to talk about the state of public education under the Trump administration, her thoughts on JB Pritzker wanting classrooms to be ‘screen free,’ and the impact of AI and other technology on […]

Liz Shulman, English teacher at Evanston Township High School and in the School of Education and Social Policy at Northwestern University, joins John Williams once again to talk about the state of public education under the Trump administration, her thoughts on JB Pritzker wanting classrooms to be ‘screen-free,’ and the impact of AI and other technology on students.

Liz Shulman, English teacher at Evanston Township High School and in the School of Education and Social Policy at Northwestern University, joins John Williams once again to talk about the state of public education under the Trump administration, her thoughts on JB Pritzker wanting classrooms to be ‘screen-free,’ and the impact of AI and other technology on students.

Mikey Shulman, Co-Founder and CEO of Suno, comes back on the podcast to answer your questions from X with Lightspeed Partner Michael Mignano. Mikey shares about Suno's growth over the past year, introducing new models, and launching their mobile app. They also address numerous questions from the audience about the potential of AI in creating realistic music, copyright issues, and the future vision for AI-generated compositions. Episode Chapters00:00 Introduction and Guest Welcome01:09 Suno's Recent Developments01:45 Mobile App and User Experience02:01 AI Music Models and Quality05:06 Community Questions and API Discussion06:43 Future of AI in Music12:14 Copyright and Legal Considerations14:24 Challenges and Opportunities in AI Music23:17 Open Source AI Models26:54 Future Enhancements and User Controls29:50 Collaborative Music Creation31:42 AI Voice Enhancement33:12 Future of Music Videos34:20 User Demographics and Live Jamming36:09 Multimodal Inputs and Personalization38:47 Blockchain and Music41:29 AI's Sense of Taste in Music44:37 Social Music and Prompting Tricks48:41 Educational Features and Future Vision52:02 Building an AI Startup58:32 Conclusion and Final ThoughtsStay in touch: www.lsvp.com X: https://twitter.com/lightspeedvp LinkedIn: https://www.linkedin.com/company/lightspeed-venture-partners/ Instagram: https://www.instagram.com/lightspeedventurepartners/ Subscribe on your favorite podcast app: generativenow.co Email: generativenow@lsvp.comThe content here does not constitute tax, legal, business or investment advice or an offer to provide such advice, should not be construed as advocating the purchase or sale of any security or investment or a recommendation of any company, and is not an offer, or solicitation of an offer, for the purchase or sale of any security or investment product. For more details please see lsvp.com/legal.

Elon Musk, a corporate billionaire and private naturalized American citizen born in South Africa, has taken an extraordinary amount of power in government since Donald Trump took office as President less than a month ago. Musk is seeking to interfere with elections in Germany and other countries around the world. Vance recently told European leaders to allow more “free speech” but what that means is use of social media and media to push authoritarianism. Dr. Stuart Shulman holds a PhD in American Politics and has done extensive teaching and leadership roles in collaborative interdisciplinary research. Additionally, as founder and CEO of Texifter, he discussed the analysis of Twitter data, his work supporting academic access to data, and federal agency review of public comments on proposed rules. Stuart and I discussed how Twitter was gamified through QAnon since 2017. He tracked QAnon, a tale of a high-up government official with a “Q-level” clearance covering nuclear weapons and related materials and tweeting about supposed confidential information. Coded language and “crumbs” were then created to entice signaling, and Trump often alluded to this through tweets. Stuart noted that in a December 1-12, 2017, dataset with 2.3 million mentions of Michael Flynn, “#followthewhiterabbit” and “the Great Awakening” and other QAnon buzzwords in the Tweets. Stuart noted how the Alternate Reality Gaming (ARG) characters often have made-up names and emojis and could have come from anywhere in the world, including Russia, China, India, and other nations that may not have the best interests of voters and citizens in western democracies. Learn more about your ad choices. Visit megaphone.fm/adchoices

The videos and images of recent airplane crashes are hard to shake.  For some, it has ignited a fear of flying – but is it warranted?The statistics say one thing, but our minds say another.  So what can we do?  Host Melanie Ng speaks with Dr. Ian Shulman, Psychologist and Clinical Director at Shift Cognitive Therapy - where even her subconscious kicks in, making an error right at the beginning of the episode, contrary to her notes!  You can learn more about Dr. Shulman at https://shiftct.com/.   We love feedback at The Big Story, as well as suggestions for future episodes. You can find us:Through email at hello@thebigstorypodcast.ca Or @thebigstoryfpn on Twitter

Jeremy Shulman is in his first season leading UT Martin and has the Seahawks in the mix in the OVC. He spent the last 14 seasons at Eastern Florida State College. He chatted with Ian Sacks and Isaac Bourne about his first impressions of Division I basketball.

This weekend's 1 in 36 guest is Gary Shulman. Gary was the Program Director of Social Services, Training Coordinator and Special Camp Fair Coordinator for Resources for Children with Special Needs, Inc. for over 24 years. He has now transitioned to the role of consultant/trainer on a private basis. Gary is also a published poet. He also serves as a volunteer Advisory Commissioner in Arlington, VA. Tune in to learn more about the virtual workshops he provides nationally, or visit: https://garyshulman.jimdo.com

Mikey Shulman is the Co-Founder and CEO of Suno, the leading music AI company. Suno lets everyone make and share music. Mikey has raised over $125M for the company from the likes of Lightspeed, Founder Collective and Nat Friedman and Daniel Gross. Prior to founding Suno, Mikey was the first machine learning engineer and head of machine learning at Kensho technologies, which was acquired by S&P Global for over $500 million.  In Today's Episode with Mikey Shulman: 1. The Future of Models:  Who wins the future of models? Anthropic, OpenAI or X? Will we live in a world of many smaller models? When does it make sense for specialised vs generalised models? Does Mikey believe we will continue to see the benefits of scaling laws? 2. The Future of UI and Consumer Apps:  Why does Mikey believe that OpenAI did AI consumer companies a massive disservice? Why does Mikey believe consumers will not choose their model or pay for a superior model in the future?  Why does Mikey believe that good taste is more important than good skills? Why does Mikey argue physicists and economists make the best ML engineers? 3. The Future of Music:  What is going on with Suno's lawsuit against some of the biggest labels in music? How does Mikey see the future of music discovery? How does Mikey see the battle between Spotify and YouTube playing out? How does Mikey see the battle between TikTok and Spotify playing out?  

The Lawyer Stories Podcast Episode 210 features Cary London, Managing Partner at Shulman and Hill in Greater New York City focusing on Civil Rights, Police Brutality, Excessive Force, Wrongful Convictions, and Personal Injury.  Cary is the Chair of the Civil Rights Division of the Brooklyn Bar Association, and a Board Member of the Brooklyn Defender Services.  Cary is also a Founding Member of Lawyer Stories Connect!  Cary's journey as a civil rights lawyer began during his tenure as a Public Defender in Brooklyn. Cary witnessed, firsthand, the systemic injustices prevalent in the criminal justice system. This experience ignited a fire within him to advocate for change and pursue justice for those who have been marginalized or wronged.  One case at a time, Cary is becoming a voice for those in need, consistently striving to create a more equitable society for all.

Check out Tory's weekly show Daytime After Dark on YouTubeFollow Tory on IG: @iamtoryshulmanFollow the show on IG: @didthatagewell TikTok: @didthatagewellpodWatch this episode this episode on YouTube and subscribe to the channel! youtube.com/@didthatagewellEmail: didthatagewell@gmail.com

Love, Norm: Inspiration of a Jewish American Fighter Pilot (Modern Jewish History) by Norman M. Shulman Amazon.com Lovenormmemoir.com Norm Shulman's relationship with his stepson Greg Levenson had always been stable and warm, but it altered when Greg decided to enlist in the Air Force at age 27. This unexpected decision brought them even closer together, and Norm came to realize that his whole family history had much support to offer Greg. Cognizant of past anti-Semitic stereotypes persisting about Jewish participation in the military, Norm wanted to help prepare Greg to feel comfortable in his own identity. So, Norm decided to write letters that connected Greg to the many Jewish military heroes who had preceded him. From Judah Maccabee to fighter pilots from today's recent history, these profiles in courage and heroism brought Greg foundation and strength, and they offer readers a breadth of knowledge from every corner of Jewish history. Norm's letters to Greg make up one core of Love, Norm; the other is Norm's own multigenerational story of Jewish military heroes. As the son of Jewish immigrants whose place in America was hard-won, Norm chronicles what it was like to feel his identity pulled in different directions and how to hold fast to it nonetheless. Love, Norm is a multifaceted retelling of inspirational profiles of famous Jewish fighters from across history, and it is also the singular story of how one man dug into his own past and found pieces to preserve his Jewish identity. Together, empathetically channeled through his heartfelt letters and remembrances, Love, Norm shares a collected wisdom with the next generation.

Jonathan Shulman, Senior Partner at McKinsey & Company, highlights the transformative potential of AI in the software industry and the evolutions needed to capture emerging market opportunities.Topics Include:AI's transformative potential in the software industry.Why AI is a massive business opportunity.Software industry evolution: Mainframe to Cloud SaaS eras.Potential entrance into a new AI-driven era.AI spend forecast: $15B to $200B by 2026.Most AI spend repurposed from existing IT budgets.Legacy software spend likely shifting towards AI.Importance of targeting specific, high-impact AI use cases.Key areas disrupted: sales, marketing, software engineering.AI's adoption rates vary by industry and function.Four waves of AI: predictive to agent-based.Most companies are still in early AI stages.Prioritize building agentic, end-to-end AI solutions.Winning companies invest disproportionately in AI innovation.Position offerings to tap into AI-specific budgets.Deliver complete workflows, not isolated point solutions.Generative AI accelerates development and iteration cycles.Scaling AI pilots remains a major industry challenge.Tool fragmentation undermines productivity and innovation.Change management critical for successful AI integration.Rethinking team roles and processes for AI deployment.Consumption-based pricing models gaining industry traction.Shift from perpetual to subscription to consumption models.Balancing value-driven and cost-efficient consumption pricing.AI market poised to redefine IT and business landscapes.Participants:Jonathan Shulman – Senior Partner, McKinsey and CompanySee how Amazon Web Services gives you the freedom to migrate, innovate, and scale your software company at https://aws.amazon/isv/

On November 2, 2016, thirty-four-year-old so-called “Supermom” Sherri Papini went out for a run near her home in Redding, California, and disappeared without a trace. Three weeks later, on Thanksgiving Day, Sherri was discovered on the side of the road in a nearby county, where she said her captors had released her. In the days that followed, Sherri claimed she had been kidnapped by two unknown Latin American women, who physically abused her, including branding her on the shoulder with the word “Exodus.” The case garnered considerable attention from the local and national media, but when it came to details on her abductors and their motives, Sherri was surprisingly tight-lipped, giving the police and FBI little to work with. In March 2022, more than five years after her supposed abduction, the nation was shocked to learn that federal agents had arrested Papini and charged her with faking her own kidnapping. A month later, Sherri pleaded guilty to the charges and was sentenced to more than a year in prison. The news was stunning and left everyone wondering, why would a seemingly ordinary and ostensibly happy mother orchestrate such a bizarre hoax?Thank you to the Incredible Dave White of Bring Me the Axe Podcast for research and Writing support!ReferencesABC News. 2016. "Missing California mom found alive after captor abandons her in restraints, sheriff says." ABC News, November 24.Ayestas, Jonathan. 2024. "Sherri Papini has yet to pay $300,000 fine for faked 2016 California kidnapping." CNN Newswire, March 26.Bella, Timothy. 2022. "A mother said she was kidnapped. Now she admits it was all a hoax." Washington Post, April 13.Bever, Lindsey, and Kristine Guerra. 2016. "Missing California mother found alive three weeks after her apparent abduction, police say." Washington Post, November 25.Bonvillian, Crystal. 2022. "Feds detail how missing mom branded, starved self in 2016 kidnapping hoax." Cox Media Group, March 9.CBS News, Sacramento. 2016. "Full text of November 30 press conference about Sherri Papini's abduction." CBS News, Sacramento, November 30.Federal Bureau of Investigation. 2022. Sherri Papini criminal complaint and affidavit. Criminal complaint, Los Angeles, CA: Federal Bureau of Investigation.Gumbel, Andrew. 2022. "California jogger Sherri Papini staged own violent kidnapping, FBI says." The Guardian, March 4.—. 2016. "Kidnapping, reverse ransom and a bounty: the strange case of Sherri Papini." The Guardian, December 30.Hurley, Beven. 2022. "Why did it take five years to charge 'supermom' Sherri Papini with fabricating her own abduction?" The Independent, March 4.Larimer, Sarah. 2016. "California mother was 'branded' and covered in bruises after apparent abduction, husband says." Washington Post, November 29.Longoria, Sean. 2016. "Mother of 2 goes missing near Redding." Record Searchlight (Redding, CA), November 4: 1.—. 2016. "Audio tells of Papini response." Record Searchlight, November 27: 1.Sabalow, Ryan. 2016. "Familty of 'supermom' holds on to hope." Sacramento Bee, November 12: 1.—. 2016. "Keep an open mind in unusual kidnap story, experts say." Sacramento Bee, December 3: B1.—. 2016. "Relative defends husband of missing 'supermom'." Sacramento Bee, November 9: A14.—. 2017. "Sheriff's office silent on Papini details." Sacramento Bee, January 31.—. 2016. "'Supermom' hasn't been seen since taking a jog." Sacramento Bee, November 8: A4.Sandhu, Amber. 2016. "Missing mom sought." Record Searchlight (Redding, CA), November 5: 1.Serna, Joseph. 2016. "A setback in kidnapping case?" Los Angeles Times, December 1: B3.Shulman, Alayna. 2016. "Sherriff gets help in search." Record Searchlight, November 8: 1.—. 2017. "Will 2018 bring more Papini details?" Record Searchlight, December 28: 6.Solis, Nathan. 2022. "Tale of abduction by Latinas fueled racial unease." Los Angeles Times, March 6: B2.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We're joined by TV personality Tory Shulman to discuss the complexities of grief, resilience, and finding humor even in the darkest moments.  + ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow our new Instagram account⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Head ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠for all things Angel Aesthetics ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠It Hurts To Be Pretty on YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow Angel Aesthetics on Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Find us on TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Shop Skincare & Merch⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ What would you like to hear on the podcast? Write us at podcast@skincarebyangel.com

Full show - FrYiday | Hillbilly hookup | News or Nope - Winter drinking and Celine Dion | Tajin souvenir | Telephone talent show | Slacker wants his parking spot vengeance | Tory Shulman is filling in for Erin today | Who gets to name the baby? | Women love men with scars | Sexy voices | Stupid stories @theslackershow @thackiswack @radioerin

Erin is on vacation in London, so our friend Tory Shulman is filling in. Don't worry - Erin will be back on Monday!

In this episode of the Lawyer Lifter Podcast, sit down with Melissa Fulgencio, Founding Attorney of Uplift Law, and her Executive Assistant Arianna Dela Cruz as they begin discussing the ongoing  Shulman v Kaplan Trial, which has been 6 years in the making, along with exploring the critical stages of trial prep.Whether you're a legal professional or a loyal listener, this podcast offers a behind-the-scenes look at what it truly takes to prepare for trial.

Show Notes: “The World Isn't Ready for What Comes After I.V.F.” by Ari Shulman, New York Times https://www.nytimes.com/2024/09/09/opinion/ivf-debate.html “Open Wallets, Empty Hearts” by Ari Shulman, The New Atlantis https://www.thenewatlantis.com/publications/open-wallets-empty-hearts   “Silicon Valley's Trendy Ethic: Effective Altruism” by Heather Zeiger, Mind Matters News https://mindmatters.ai/2024/09/silicon-valleys-trendy-ethic-effective-altruism/ “I was adopted from China as a baby. I'm still coming to terms with that” by Cindy Zhu Huijgen, New York Times https://www.nytimes.com/2024/09/15/opinion/china-adopted-babies-identity.html   The New Atlantis Donation Page:  https://www.thenewatlantis.com/donate   CBHD Donation Page:  https://www.tiu.edu/giving/bioethics/

103.7 The Buzz

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Hurricane aid for people with diabetes, Medtronic safety warning, stem cell updates for type 1, new study about teens and young adults with type 1, and Ryan Reed returns to racing. Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Hurricane Insulin efforts XX Medtronic has notified customers that battery issues with its Minimed 600 and 700 series insulin pumps could cause the devices to stop delivering insulin significantly sooner than expected. A “low battery pump” alert, intended to signal up to 10 hours of remaining battery life, may be displayed on the device even if much less time is left. Medtronic told customers they could contact the company to determine the need for a replacement pump. Medtronic said it received 170 reports of hyperglycemia and 11 reports of diabetic ketoacidosis in the U.S., from January 2023 to September 2024, potentially related to the issue. Pump models including the Minimed 630G, 670G, 770G and 780G systems are affected by the notice. https://www.medtechdive.com/news/Medtronic-Minimed-insulin-pumps-recall-battery-life/729019/ XX A woman has undergone a stem-cell therapy made from her own cells, to treat her type 1 diabetes. Researchers in China discovered the woman did not need to use insulin 75 days after the procedure, and that the stem-cell derived islet cells she was injected with had been engrafted inside her abdomen. the case is the first of its kind, and two more people have been enrolled in the clinical trial in China since, researchers involved in the study told Medical News Today. Other stem-cell based therapies for type 1 and type 2 diabetes are also currently in development and in trials. For this case study, researchers based in Tianjin First Central Hospital, Nankai University, Tianjin, China took fat cells from a 25 year-old woman with type 1 diabetes, and chemically induced them to behave as pluripotent stem cells, a type of cell that can develop into other types of cell. They then used these to create islet cells, which typically exist in the pancreas and create insulin, a hormone that regulates levels of glucose (sugar) in the bloodstream. The patient in this case study had previously had two liver transplants and a failed pancreas transplant due to complications that had arisen due to her diabetes. The induced islet cells made from the patient's own cells were then injected between the skin and abdominal muscles. Researchers discovered that these successfully engrafted in the patient, including growing their own vasculature. Before the procedure she produced enough insulin to reach her target glycemic range 43.18% of the time, and 4 months later this increased to 96.2% of the time. She was also shown to have lower glycated hemoglobin, which indicated long-term systemic glucose levels at a non-diabetic level.   https://www.medicalnewstoday.com/articles/stem-cell-therapy-reverses-type-1-diabetes-in-groundbreaking-case-study XX The state of Texas is accusing major pharmacy benefit managers and drug companies of colluding to raise the cost of insulin.   Texas alleged drug manufacturers Eli Lilly, Novo Nordisk and Sanofi raise the price of insulin and then pay an undisclosed amount back to PBMs Optum Rx, Express Scripts and CVS Caremark through a quid pro quo agreement. PBMs then give preferred status on its standard formularies to drugs with the highest list prices, the state said. Insulin costs $2 to produce and could be purchased for $20 in the 1990s but now costs up to $700, the Office of the Attorney General of Texas wrote in a news release. The filing goes so far as to describe a LinkedIn group these executives would use to discuss insulin pricing tactics. The Federal Trade Commission (FTC) recently sued Optum Rx, Express Scripts and Caremark for rising insulin prices and anticompetitive practices. The PBMs reject the FTC's findings. Drug manufacturers were not included in the lawsuit. Texas' lawsuit also noted the consolidation in the PBM market, arguing it gives PBMs a “disproportionate amount of market power.” Nearly 40 PBM entities have now been consumed by UnitedHealth Group, Cigna and CVS Caremark. https://www.fiercehealthcare.com/payers/texas-sues-pbms-manufacturers-over-insulin-conspiracy XX Canadian teens and young adults living with diabetes face double the risk of hospitalizations and emergency room visits compared with younger children with the condition, say doctors suggesting changes to how care is organized for affected families. In the October issue of the journal The Lancet Diabetes and Endocrinology, Dr. Meranda Nakhla, a pediatric endocrinologist at the Montreal Children's Hospital, and her team used Quebec health administrative data to estimate the risk of gaps in regular diabetes care for complications in children under 10, and adults up to age 23.   "With adolescents and young adults, [the complication]  tends to be more related to an insulin omission and maybe just feeling burnt out from having diabetes and just not wanting to deal with it," Nakhla said. "They may stop taking insulin and a day later end up in the emergency room with diabetic ketoacidosis." Part of the challenge, Nakhla said, is for parents to take a step back from managing all aspects of their child's diabetes to a more supportive role that allows the child to have more autonomy. What's new about the Quebec findings is they highlight how gaps in diabetes care visits start at a younger age than previously looked at, said Dr. Rayzel Shulman, a pediatric endocrinologist at Toronto's Hospital for Sick Children. Since the brains of adolescents and young adults aren't fully developed, planning ahead, thinking about the consequences of their actions and controlling impulses differs from their parents. As part of an ongoing study, Shulman's team uses text messages to send adolescents and young adults appointment reminders as well as monthly diabetes messages. They recently added an artificial intelligence chat bot programmed with answers from trusted sources. https://www.cbc.ca/news/health/diabetes-pediatric-1.7345526 XX A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and Zepbound has filed a lawsuit against the Food and Drug Administration (FDA) for declaring an end to the shortage, effectively halting the sale of “copycat” versions of these drugs.   On Oct. 2, the FDA announced that the nearly two-year-long shortage of tirzepatide, the active ingredient in Mounjaro and Zepbound, had ended. This was after the agency said it had confirmed the manufacturer, Eli Lily, had a manufacturing capacity that “can meet the present and projected national demand.”     With the shortage over, the ability of compounding pharmacies to sell unbranded, replicated versions of these drugs came to a near halt. There are two types of compounding pharmacies: 503A and 503B. The Outsourcing Facilities Association (OFA) represents 503B compounding pharmacies, which can create prescription-specific compounded drugs as well as bulk orders.   The OFA and the compounding pharmacy North American Custom Laboratories filed their lawsuit against the FDA on Monday, alleging the agency was “abruptly depriving patients of much needed treatment and artificially raising drug prices.”   “Ignoring evidence that the shortage persists, FDA removed Tirzepatide from the shortage list without notice, without soliciting input from affected parties and the public, and without meaningful rationale,” said their complaint.   The evidence that the plaintiffs cited for the shortage persisting was that the FDA noted in its announcement that “patients and prescribers may still see intermittent localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies.”   Eli Lilly made a similar statement after the shortage was declared over, saying, “Patients' experiences looking for a particular dose of medicine in their local pharmacies may vary. The supply chain is complex, especially for refrigerated medicines, and there may be many reasons why a particular pharmacy does not have a particular dose of the medicine in stock. ” https://thehill.com/policy/healthcare/4922234-trade-group-sues-fda-over-ending-mounjaro-zepbound-shortage/ XX New project in Europe to provide data to enable more people with diabetes who use insulin to work as commercial pilots and air traffic controllers. The European Union Aviation Safety Agency project focuses mainly on pilots and air traffic controllers, but the data being collected will apply to cabin crew and passengers with diabetes as well   currently only three countries in Europe — the United Kingdom, Ireland, and Austria — allow them to obtain a license that enables them to fly commercially, under a strict protocol that was first launched by the UK Civil Aviation Authority in 2012. The Irish Aviation Authority joined in 2015, and Austro Control followed in 2016.     https://www.medscape.com/viewarticle/eu-program-aims-ensure-safety-pilots-who-use-insulin-2024a1000ia6 XX Edgepark commercial XX The two-time Xfinity Series winner was competing at Talladega in McAnally-Hilgeman Racing's No. 91 truck for his first start of the season. The last time Reed drove in a NASCAR event came last fall at Las Vegas Motor Speedway in the Xfinity Series, and his most recent Truck start came in the spring of 2021 at Darlington Raceway.   “I couldn't stop making mistakes early on,” Reed said. “The truck was so fast. I think more than anything I'm really proud of myself for being able to get out there and make aggressive pushes and be able to kind of rise to the occasion.”   See also Grant Enfinger Wins Talladega, Advances to Championship 4 Despite the speed, Reed's truck burst into flames shortly after crossing the finish line. Reed said he stared at the door of teammate Christian Eckes while he crossed the line in the middle of a multi-truck pileup.     “Gosh, we could go anywhere we wanted today,” Reed told Frontstretch. “I made a lot of mistakes, but we put ourselves in position at the end. I hate that Bill [McAnally] has torn up race trucks.”   Friday marked Reed's sixth start in the past six years in Truck and Xfinity equipment, something Reed said might have added some doubt.   “When you're sitting on the couch every weekend, you think you can do it,” he reflected. “I remember I used to race every single weekend, I know how to get around these plate tracks, but you don't know, right?   “It's really gratifying to come off the couch and remind myself, like ‘hey I can still do this,' at least at superspeedways. I think I can do it at other tracks too.”     The day ended in a combination of a career-best Truck Series finish and a ball of fire for Ryan Reed in his return to NASCAR Craftsman Truck Series competition on Friday (Oct. 4).   https://frontstretch.com/2024/10/04/ryan-reed-scores-career-best-finish-in-truck-series-return/ XX Join us again soon!

In this AI in Retail Podcast episode, we dive into the latest advancements shaping the future of commerce with Stacey Shulman, Intel's VP of Consumer, Education, and Healthcare. Stacey shares her journey from merchant to AI pioneer, offering insights into Intel's innovative work in the Network and Edge (NEX) division and the broader impact of AI on retail. From the evolution of self-checkout to generative AI, explore how Intel is redefining the retail experience for both businesses and consumers. Key Insights: - AI's Rapid Transformation of Retail: Stacey highlights how AI is quickly revolutionizing the retail industry, reshaping everything from operational processes to personalized customer experiences. Intel leads the way in integrating AI solutions that are fundamentally changing how retailers operate and engage with consumers. - Intel's NEX Division and Retail Focus: Discover how Intel's Network and Edge (NEX) division goes beyond brick-and-mortar stores to encompass the entire retail ecosystem, including social media, e-commerce, and supply chains. - AI in Retail – Beyond the Consumer: Stacey discusses AI's role in improving employee retention and training, showcasing how assistive technologies are boosting workforce productivity across industries like retail, healthcare, and education. Stay ahead of the AI curve! Subscribe to the AiR email list for cutting-edge AI insights: https://rethink.industries/air-top-ai-leaders-2024/

In this powerful episode of AGE BETTER, I sit down with Joyce Shulman co-founder of 99 Walks, to tackle one of the most urgent public health crises facing America today: the loneliness epidemic. Recently declared an epidemic by the U.S. Surgeon General, loneliness affects millions of people, particularly those in midlife. Joyce, who is transitioning from leading 99 Walks to focus on building programs aimed at helping women in midlife transitions, brings valuable insights into how we can address this growing issue.    WHAT YOU'LL LEARN:  - The True Impact of Loneliness: Joyce and I explore how loneliness isn't just an emotional issue, but one with significant mental and physical health consequences—comparable to smoking 15 cigarettes a day.  - Midlife & Loneliness: Why this phase of life can be especially isolating, and how we can reverse this trend by nurturing social connections.  - Practical Steps to Combat Loneliness: Whether it's through building casual friendships, walking together, or becoming more active in your community, Joyce shares actionable ways to reconnect.  - The Role of Technology: While social media can offer meaningful connections, it can also amplify feelings of isolation. We explore how to use technology to foster, rather than hinder, real connection.  - Why Friendship Requires Effort: Learn why maintaining relationships requires intentionality and action, especially as we age.  - Community & Connection: Discover how getting involved in your local community can play a crucial role in combating feelings of loneliness.  - The Pandemic's Role: The impact of the COVID-19 pandemic on social isolation and what we can do to heal from its lingering effects.    Whether you're feeling isolated yourself or looking for ways to help a loved one, this episode offers insights and tools to take the first steps toward building a stronger, more connected life.    FOLLOW & SUBSCRIBE   Be sure to subscribe to AGE BETTER with Barbara Hannah Grufferman for more conversations that help you take charge of your health and well-being as you age.   Learn more about your ad choices. Visit megaphone.fm/adchoices

Daily Blast Live co-host Tory Shulman shares her struggles with depression, alcohol and her journey of grief after losing her mother. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Unlock Your Potential, I sit down with Louis Shulman, a dynamic entrepreneur and the host of the popular podcast, "Louis and Kyle Show." We dive into his entrepreneurial journey, exploring the early challenges and key lessons he's learned along the way. Louis shares valuable insights from his podcasting experience, revealing what it takes to succeed in today's competitive landscape. We also discuss what makes up the DNA of an entrepreneur and why embracing a “more work, less play” mentality can be crucial to success. Louis sheds light on the contrasts between entrepreneurship and traditional employment, offering advice on why starting small and focusing on "boring" businesses can be a smart path to long-term success. We even explore how AI software is changing the game and how entrepreneurs can leverage it to stay ahead. This episode is packed with actionable advice and inspiring stories for anyone looking to break into the entrepreneurial world. Check Out More of Louis' Content Here

ERShares Founder Joel Shulman goes in-depth on what’s being called the first ever private-public crossover ETF, the appropriately named Entrepreneur Private-Public Crossover ETF (XOVR). VettaFi’s Todd Rosenbluth discusses Nvidia from an ETF angle, highlighting products with varying exposure to the...

How do you tell others about G-d? Do you get nervous when sharing your faith? Join guest speaker, Rabbi Mark Shulman of Beth El Gibor, as he hastens us to bring the news of the Messiah to others with boldness and courage. The L-rd will support you if you prioritize sharing His love with others. Do not let life distract you from such an important purpose. Be encouraged today!Acts 17.1-4; Acts 17.10-12; Joshua 1.9; Ephesians 3.12-13; 1 Corinthians 10.13; Acts 17.16-20; Acts 17.22-25; Acts 17.29Prayer Requests or send an email to info@bethhallel.orgCBH WebsiteDonateYouTube Channel

Most of the hype around AI has revolved around its text capabilities, and the powers of LLMs like ChatGPT. But Suno is focusing on the unsung hero of AI - music. Suno is building a future where anyone can make good music - all you need to do is type in a prompt, and out will come a song that's never existed before. This week, we're revisiting a conversation with Mikey Shulman, CEO and Co-Founder of Suno. He joined Lightspeed Partner and host Michael Mignano earlier this year to talk through the intricacies of programming for sound, and what this technology could mean for music. Episode Chapters (00:00) Introduction to Mikey Shulman and Suno (04:03) How transcribing S&P earnings calls inspired Suno (08:41) There's no Common Crawl for audio - they had to make their own (12:37) Hacking text-to-speech to make music (16:25) What's the product market fit for generative music?  (21:15) How will AI change the format of music? (28:44) Suno's highlight reel so far (31:39) Designing with the end user in mind (38:26) Can AI transcend the creativity ceiling?  (40:48) How does Mikey think regulation and music rights will shake out? (46:19) Is Suno hiring? Stay in touch: www.lsvp.com X: https://twitter.com/lightspeedvp LinkedIn: https://www.linkedin.com/company/lightspeed-venture-partners/ Instagram: https://www.instagram.com/lightspeedventurepartners/ Subscribe on your favorite podcast app: generativenow.co Email: generativenow@lsvp.com The content here does not constitute tax, legal, business or investment advice or an offer to provide such advice, should not be construed as advocating the purchase or sale of any security or investment or a recommendation of any company, and is not an offer, or solicitation of an offer, for the purchase or sale of any security or investment product. For more details please see lsvp.com/legal.

Slappin' Glass sits down this week with the newly hired Head Coach of Central Arkansas MBB, John Shulman! In a wildly entertaining and thoughtful conversation the trio dive into Coach Shulman's thoughts on BLOB defenses, along with the value of being unpredictable in them, and discusses his preference of switching on defense and "reading the room" as a coach during the always fun "Start, Sub, or Sit?!"To join coaches and championship winning staffs from the NBA to High School from over 60 different countries taking advantage of an SG Plus membership, visit HERE!

John Shulman is entering his first season as the Head Men's Basketball Coach at The University of Central Arkansas. In his previous five seasons at the helm of the University of Alabama Huntsville, Shulman posted a record of 112-39 and led the Chargers to five consecutive D2 NCAA tournament berths. Overall, Shulman has a career coaching record of 257-185.Shulman also served as the head coach at Tennessee Chattanooga from 2004 to 2013. While at Chattanooga, the Mocs earned two D1 NCAA tournament appearances following a pair of Southern Conference championships. The second winningest coach in Chattanooga history, Shulman also won four SoCon North Division championships.In 2005, he was named as the top collegiate coach in Tennessee thanks to a season that included a NCAA tournament berth and Chattanooga's first win in 80 years over in-state foe Tennessee.Prior to taking over the top spot at Chattanooga, Shulman served as the team's associate head coach from 2002 to 2004, and that came after stints as an assistant at Wofford, Tennessee Tech, and East Tennessee State.If you're looking to improve your coaching please consider joining the Hoop Heads Mentorship Program. We believe that having a mentor is the best way to maximize your potential and become a transformational coach. By matching you up with one of our experienced mentors you'll develop a one on one relationship that will help your coaching, your team, your program, and your mindset. The Hoop Heads Mentorship Program delivers mentoring services to basketball coaches at all levels through our team of experienced Head Coaches. Find out more at hoopheadspod.com or shoot me an email directly mike@hoopheadspod.comMake sure you're subscribed to the Hoop Heads Pod on iTunes or wherever you get your podcasts and while you're there please leave us a 5 star rating and review. Your ratings help your friends and coaching colleagues find the show. If you really love what you're hearing recommend the Hoop Heads Pod to someone and get them to join you as a part of Hoop Heads Nation.Grab your notebook as you listen to this episode with John Shulman, Head Men's Basketball Coach at the University of Central Arkansas.Website - https://ucasports.com/sports/mens-basketballEmail - Jshulman@uca.eduTwitter - @coachjshulmanVisit our Sponsors!Dr. Dish BasketballOur friends at Dr. Dish Basketball are ready to fire up your team's training with $4,000 the Dr. Dish CT+ with a trade-in during their July Super Sale. Trade-in your machine, any make or model in any condition even if it's a competitor's model, and get the industry's leading shooting machine into your gym now. drdishbasketball.comFast Model SportsFastModel Sports has the most compelling and intuitive basketball software out there! In addition to a great product, they also provide...

Today I speak with IFBB Bikini Pro Brittany Shulman, a wife, mother, and former gymnast who works in finance. She started lifting after leaving gymnastics and two friends introduced her to bodybuilding. She competed in her first show in 2017 and then took a couple years off to get married and have a baby. She tried to return to the stage in 202, but got derailed by COVID. She then found Paul Revelia and first year competing with him in 2022 and earned her pro card at Ben Weider Naturals. She returned in 2023 and won, qualifying her to the 2024 Olympia.   She will soon be launching her coaching business soon, mostly focusing on transformation/lifestyle clients!   TOPICS COVERED -balance of working mom and competing -deciding to return to the stage -getting of birth control -qualifying for the Olympia -prepping as a family -prioritizing communication -postpartum fitness -navigating mom guilt -hobbies outside of bodybuilding   CONNECT WITH CELESTE: Website: http://www.celestial.fit Instagram: https://www.instagram.com/celestial_fit/ All Links: http://www.celestial.fit/links.html CONNECT WITH BRITT: Instagram: https://www.instagram.com/brittshuls_ifbbpro/   TIME STAMPS 1:00 introduction 5:20 journey to Pro card 16:23 feedback from turning Pro 24:05 planning for the Olympia 30:25 approaching prep with gratitude 33:48 setting an example for her daughter 37:10 Prep as a family decision 44:06 relationship with her husband 51:40 deciding to become a coach 56:30 body after baby 61:29 navigating mom guilt 64:07 practicing Muay Thai  76:05 getting bodywork done 79:55 advice for competitors    CLICK HERE TO SIGN UP FOR THE FREE FOOD RELATIONSHIP COACHING SERIES   CLICK HERE TO SIGN UP FOR THE FREE POST SHOW BLUES COACHING SERIES   LEARN MORE AND APPLY FOR MY 5 WEEK FOOD RELATIONSHIP HEALING & DISCOVERY COACHING PROGRAM   FOR OTHER FREE RESOURCES, LIVE EVENTS, AND WAYS TO WORK WITH CELESTE CLICK HERE

Barry Shulman is a seasoned talent advisor, executive search expert, and Predictive Index expert with over 30 years of experience working with various executive teams. He began his career in New York City on Madison Avenue as a recruiter before founding his management consulting firm in Silicon Valley during the early 1990s, navigating the ups and downs of the tech boom and bust. Barry is known for his deep understanding of organizational dynamics and innovative use of predictive analytics to enhance workplace performance. His insights are sought after not only for recruiting and placing top executives but also for transforming organizational structures and optimizing team performance. In this episode… In today's business landscape, finding and managing the right talent remains a critical challenge for leaders across industries. The complexities of building cohesive teams that drive organizational success can often seem daunting, especially when traditional hiring practices fail to yield the desired results. So, how do you recruit the right talent without making costly mistakes? Barry Shulman, with his deep expertise in executive search and talent optimization, provides practical solutions to these challenges. By leveraging advanced assessment tools like the Predictive Index, Barry helps leaders design winning teams and secure top talent. His methodology focuses on identifying behavioral and cognitive patterns in employees and aligning their capabilities with the strategic objectives of their employers. Barry's methods not only refine the hiring process but also enhance overall team performance and organizational health. Tune in to this episode of the Smart Business Revolution Podcast as John Corcoran interviews Barry Shulman, a talent advisor and executive search expert at Shulman Associates, about how predictive analytics can revolutionize talent management strategies. Barry talked about his strategic move to Silicon Valley and how he navigated the challenges of the dot-com bust. They also discussed the significance of the Predictive Index and how it transforms talent management.

Why Walk? Joyce Shulman The Not Old Better Show Prevention Magazine Interview Series Welcome to an exciting edition of Not Old Better Prevention Magazine Interview series on radio and podcast, brought to you by ProLon.  Remember, 52000+ people are using Prolon to gain more energy, eliminate sugar cravings, and just feel better.Today's spotlight is on Joyce Shulman, co-founder and CEO of 99 Walks and an advocate for women's wellness through walking. Joyce Shulman, famous for her TedTalk titiled, How More Walking Leads to Less Loneliness is also revered as the "Pack Leader," brings to the fore the incredible power of simple steps in forging not only physical fitness but also profound community connections. Joyce Shulman is also Author, Why Walk? Her journey as the daughter of a coach and her unyielding passion as an idea junkie have propelled her to spearhead a movement aimed at getting a million women walking, driven by the belief that walking is a gateway to reduced loneliness and enhanced collective well-being. Today, we're set to uncover how walking can play a crucial role in managing stress, combating depression, and enhancing overall mood, with Joyce's expert insights tailored for our listeners, particularly those over 60. With her book, 'Why Walk?, Joyce has laid down a compelling narrative about the multifaceted benefits of walking, making a compelling case for why walking is more than just physical activity but a lifeline to emotional and mental health. Stay tuned as we explore these themes, drawing on Joyce's profound understanding of walking's impact. Whether you're looking to improve your physical health, find mental clarity, or connect more deeply with others, Joyce's experiences and the community at 99 Walks offer both inspiration and practical advice that resonate with everyone, especially our aging population and their families. Get ready to be inspired and perhaps, take the first step towards a healthier, more connected life. My thanks to  Prevention Magazine Interview series brought to you by ProLon.  Remember, 52000+ people are using Prolon to gain more energy, eliminate sugar cravings, and just feel better. My thanks to Joyce Shulman, Author, Why Walk?  My thanks always to Executive Producer Sam Heninger for all his work on the show and my thanks to you our wonderful audience here on radio and podcast.  Be well, be safe and Let's Talk About Better™ The Not Old Better Prevention Magazine Interview series on radio and podcast. Thanks, everybody and we'll see you next week.

Even though the American labor market is currently stronger than it has been in decades, earlier this year Big Tech companies were laying off workers at an alarming pace. Economists struggled to understand why some 25,000 tech workers were losing their jobs, even as the media panicked about whether those layoffs were a warning sign of an oncoming recession. University of Washington Professor Jeff Shulman joins us to uncover the real reasons behind Big Tech's layoffs, and to explain their implications for workers.  Jeffrey Shulman is a professor at the Foster School of Business at the University of Washington. He's also a podcaster and filmmaker with a diverse range of expertise in pricing, entrepreneurial marketing, and product management. As a professor, he is known for his innovative research and teaching methods that delve into the intricacies of economic principles and their practical applications in the business world. Recently, Shulman has gained recognition for his insightful commentary on the highly publicized layoffs in the tech industry.   More from Professor Shulman: Nearly 25,000 tech workers were laid off in the first weeks of 2024. Why is that? Why widespread tech layoffs keep happening despite a strong U.S. economy How To Succeed In Product Management on Apple Podcasts How To Succeed In Product Management on Spotify Website: http://pitchforkeconomics.com Twitter: @PitchforkEcon Instagram: @pitchforkeconomics Nick's twitter: @NickHanauer